ArticleFrontiers in microbiology2018
Circulating Plasma MicroRNA-208a as Potential Biomarker of Chronic Indeterminate Phase of Chagas Disease.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- MicroRNA Responses Associated with Vector-Borne Diseases in Humans and Arthropod Vectors: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- NinoaPathogens (Basel, Switzerland) · 2024Article
- Identification of Chagas disease biomarkers using untargeted metabolomics.Scientific reports · 2024Article
- The End Justifies the Means: Chagas Disease from a Perspective of the Host-Life (Basel, Switzerland) · 2024Review
- Unraveling the role of miRNAs as biomarkers in Chagas cardiomyopathy: Insights into molecular pathophysiology.PLoS neglected tropical diseases · 2024Review
- Discovery of circulating miRNAs as biomarkers of chronic Chagas heart disease via a small RNA-Seq approach.Scientific reports · 2024Article
- Cytokine Networks as Targets for Preventing and Controlling Chagas Heart Disease.Pathogens (Basel, Switzerland) · 2023Review
- Circulating microRNAs as biomarkers of Chagas cardiomyopathy.Frontiers in cardiovascular medicine · 2023Article
- Comparative microRNA profiling ofFrontiers in cellular and infection microbiology · 2023Article
- Plasma-derived exosomal miRNA as potential biomarker for diagnosis and prognosis of vector-borne diseases: A review.Frontiers in microbiology · 2023Review
- Modulation of miR-145-5p and miR-146b-5p levels is linked to reduced parasite load in H9C2 Trypanosoma cruzi infected cardiomyoblasts.Scientific reports · 2022Article
- Circulating MicroRNAs and myocardial involvement severity in chronic Chagas cardiomyopathy.Frontiers in cellular and infection microbiology · 2022Article
- Blood DNA methylation marks discriminate Chagas cardiomyopathy disease clinical forms.Frontiers in immunology · 2022Article
- Highlighting the interplay of microRNAs fromParasitology · 2021Review
- Circulating miR-146a as a possible candidate biomarker in the indeterminate phase of Chagas disease.Biological research · 2021Article
- Physical Exercise Training and Chagas Disease: Potential Role of MicroRNAs.Arquivos brasileiros de cardiologia · 2021Review
- Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease.International journal of molecular sciences · 2021Article
- Does Galectin-3 (Myocardial Fibrosis Biomarker) Predict Progression in Chagas Disease?Arquivos brasileiros de cardiologia · 2021Article
- Human microRNAs in host-parasite interaction: a review.3 Biotech · 2020Review
- The Thymus in Chagas Disease: Molecular Interactions Involved in Abnormal T-Cell Migration and Differentiation.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas cardiomyopathy is the most severe clinical manifestation of chronic Chagas disease. The disease affects most of the Latin American countries, being considered one of the leading causes of morbidity and death in the continent. The pathogenesis of Chagas cardiomyopathy is very complex, with mechanisms involving parasite-dependent cytopathy, immune-mediated myocardial damage and neurogenic disturbances. These pathological changes eventually result in cardiac myocyte hypertrophy, arrhythmias, congestive heart failure and stroke during chronic infection phase. Herein, we show that miR-208a, a microRNA that is a key factor in promoting cardiovascular dysfunction during cardiac hypertrophy processes of heart failure, has its circulating levels increased during chronic indeterminate phase when compared to cardiac (CARD) clinical forms in patients with Chagas disease. In contrast, we have not found altered serum levels of miR-34a, a microRNA known to promote pro-apoptotic role in myocardial infarction during degenerative process of cardiac injuries thus indicating intrinsic differences in the nature of the mechanisms underlying the heart failure triggered by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.